Glioblastoma Multiforme Treatment Market – By Treatment (Surgery, Radiation, Targeted, Chemotherapy, Immunotherapy), Drug Class (Temozolomide, Bevacizumab, Lomustine), Dosage Form (Oral, Parenteral), Gender, End-use - Global Forecast (2024 – 2032)

Glioblastoma Multiforme Treatment Market – By Treatment (Surgery, Radiation, Targeted, Chemotherapy, Immunotherapy), Drug Class (Temozolomide, Bevacizumab, Lomustine), Dosage Form (Oral, Parenteral), Gender, End-use - Global Forecast (2024 – 2032)

Glioblastoma Multiforme Treatment Market Size

Glioblastoma Multiforme Treatment Market size was valued at USD 2.9 billion in 2023 growing at a CAGR of 8.6% from 2024 and 2032, driven by factors such as the rising prevalence of glioblastoma.

To get key market trends

  Download Free Sample

For instance, as per the report published by American Brain Tumor Association, it has been estimated that glioblastomas represent about 14% of all primary brain tumours. On average, more than 12,000 glioblastoma cases are diagnosed each year in the U.S. Thus, the rapid increase in the prevalence of glioblastoma globally is the major factor that is anticipated to increase the demand for novel drug therapeutics and treatment procedures, thereby boosting the market growth.

Moreover, increase in investments in R&D by pharmaceutical companies and research institutions are leading to the discovery of new treatment modalities. Clinical trials and studies exploring immunotherapy, gene therapy, and personalized medicine are expanding the treatment landscape for glioblastoma multiforme that is anticipated to foster the growth of the market.

Glioblastoma (GBM), also referred to as a grade IV astrocytoma, is a fast-growing and aggressive brain tumor. It is the most malignant and pervasive subtype of glioma and is the most common primary brain tumor in adults. GBM has been classified into isocitrate dehydrogenase (IDH) wild-type and mutant variants. IDH variants bear the cytosine-phosphate-guanine (CpG) island methylation phenotype (G-CIMP).
 

What are the growth opportunities in this market?

 Download Free Sample

Glioblastoma Multiforme Treatment Market Trends

• The increasing prevalence of glioblastoma significantly drives the growth of the market. For instance, as per the report published by the National Brain Tumor Society, it has been reported that glioblastoma (GBM) is one of the most complex, deadly, and treatment-resistant cancers. Also, the report stated that the five-year survival rate for glioblastoma patients is only 6.9%, and the average length of survival for glioblastoma patients is estimated to be only 8 months. Therefore, the high prevalence of glioblastoma necessitates an increasing demand for better treatment options, thereby driving the market growth.
• Moreover, the growing patient population necessitates more comprehensive healthcare infrastructure and supportive services. Also, pharmaceutical companies are incentivized to invest in innovative solutions, fostering competitive dynamics that enhance the quality and availability of glioblastoma multiforme treatments.

Glioblastoma Multiforme Treatment Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

Based on the treatment, the global market is classified into surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating field therapy, and immunotherapy. The radiation therapy segment dominated the market with revenue of USD 826.2 million in 2023.

• The rise in technological innovations such as intensity-modulated radiotherapy (IMRT), stereotactic radiosurgery (SRS), and proton therapy, enhance the precision and efficacy of radiation treatments. These advancements reduce side effects and improve patient outcomes, making radiation therapy more appealing.
• Moreover, the increased awareness of brain cancers and improved diagnostic techniques lead to earlier detection of glioblastoma multiforme. Early diagnosis often results in better treatment planning and outcomes, contributing to the market growth during the forecast period.

Learn more about the key segments shaping this market

 Download Free Sample

Based on the drug class, the global glioblastoma multiforme treatment market is classified into temozolomide, bevacizumab, lomustine, and carmustine wafers. The temozolomide segment dominated the market with market share of 40.2% in 2023.

• Temozolomide is a standard treatment for glioblastoma multiforme, often used in combination with radiotherapy. Its efficacy in improving survival rates supports its continued use and growth in the market.
• Also, advances in diagnostic technologies are enabling earlier and more accurate diagnosis of glioblastoma multiforme, leading to timely initiation of treatments with the help of chemotherapy such as temozolomide along with radiation therapy.
• Thus, the increased awareness among healthcare professionals and patients pertaining to the benefits of temozolomide for glioblastoma, coupled with growing adoption of chemotherapy is fuelling the market growth.

Based on dosage form, the glioblastoma multiforme treatment market is classified into oral and parenteral. The oral segment is expected to reach USD 3.8 billion in 2032.

• The ongoing research and development with continuous innovations in drug delivery systems have enhanced the efficacy and bioavailability of oral treatments. This includes the development of formulations that improve drug absorption and target delivery to the brain.
• Moreover, newer oral therapies are designed to cross the blood-brain barrier more effectively and target tumor cells specifically, potentially improving survival rates with glioblastoma multiforme.
• Therefore, recent approvals of novel oral medications by regulatory authorities is expected to augment the segmental growth.

Based on gender, the glioblastoma multiforme treatment market is classified into male and female. The male segment is expected to exhibit 8.8% CAGR between 2024 - 2032.

• Glioblastoma multiforme tends to have a higher incidence rate in males compared to females. For instance, according to the article Sex-Specific Differences in Glioblastoma published by National Institute of Health (NIH) reported that the incidence of GBM is 1.6 times higher in men than women. This natural demographic skew increases the market size for male-specific treatments.

Based on end-use, the glioblastoma multiforme treatment market is classified into hospitals, cancer treatment centers, ambulatory surgical centers, and other end-users. The hospitals segment is expected to reach USD 2.5 billion and is anticipated to exhibit 8.9% CAGR between 2024 - 2032.

• The availability of advanced diagnostic tools such as MRI and PET scans and treatment options in the hospitals including surgery, radiation therapy, and chemotherapy are the major factors that attracts more patients to hospitals.
• Also, hospitals typically have specialized neuro-oncology departments and multidisciplinary teams comprising neurosurgeons, oncologists, radiologists, and other specialists. This specialized care ensures comprehensive treatment for glioblastoma multiforme patients, making hospitals a preferred choice.
• Furthermore, several hospitals especially large and academic medical centers, conduct clinical trials for new treatments. Patients with glioblastoma multiforme may prefer hospitals to gain access to experimental therapies that are not available in other settings. 

Looking for region specific data?

 Download Free Sample

In 2023, North America secured a substantial market share of 39.5% in the global glioblastoma multiforme treatment market and is expected to dominate throughout the forecast period.

• North America is at the forefront of adopting cutting-edge technologies in medical treatments. Advances in imaging technologies, surgical techniques, and radiotherapy improve glioblastoma treatment outcomes, thereby fostering market growth.
• Also, Also, the presence of key pharmaceutical and biotechnology companies in North America that are actively involved in the development of glioblastoma multiforme treatment often conducts clinical trials for the launch of new GBM treatments. Thus, the strong presence of key market players leads to innovation and advancement in therapies, thereby supporting the market growth.
• Furthermore, government initiatives and funding for cancer research including specific programs focused on brain cancer by National Institutes of Health (NIH) provide a robust foundation for market growth.

Germany to experience the highest growth rate in the Europe market.

• Germany boasts a robust healthcare infrastructure with advanced medical facilities and a well-developed network of hospitals and clinics. This infrastructure supports the diagnosis and treatment of glioblastoma multiforme.
• Moreover, increase in awareness and education pertaining to glioblastoma multiforme, its symptoms, and treatment options leads to early detection and intervention, contributing to market growth by increasing the demand for treatment options.

The Asia Pacific glioblastoma multiforme treatment market is expected to grow with a significant CAGR of 9% during the forecast period.

• The rising prevalence of glioblastoma multiforme in the region is a significant driver attributed to factors such as aging population, changing lifestyles, and environmental factors.
• Further, India's emergence as a hub for medical tourism attracts international patients seeking affordable yet high-quality treatment options including for glioblastoma multiforme. This influx of medical tourists boosts the demand for glioblastoma multiforme treatment, thereby stimulating the regional market growth. 
• Moreover, collaborations between pharmaceutical companies, research institutions, and healthcare organizations in the region facilitate the development and commercialization of novel therapies, further propelling market growth.

Glioblastoma Multiforme Treatment Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies that manufacture glioblastoma multiforme treatment products vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for glioblastoma multiforme treatment.

Glioblastoma Multiforme Treatment Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are into clinical phase development. Prominent players operating in the market are as mentioned below

• Amgen Inc.
• Amneal Pharmaceuticals
• Curtana Pharmaceuticals
• Denovo Biopharma
• Eisai Co. Ltd. (Gliadel)
• F. Hoffmann La Roche Ltd (Genetech USA)
• Karyopharm Therapeutics
• Merck & Co. Inc.
• Novocure GmbH
• Pfizer, Inc.
• Sumitomo Dainippon Pharma Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries

Glioblastoma Multiforme Treatment Industry News

• In November 2023, Rznomics Inc., a South Korea based biopharmaceutical company announced that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for RZ-001, for the treatment of patients with glioblastoma (GBM). This strategy is expected to enhance the company’s outreach to untapped economies.

The glioblastoma multiforme treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments

Click here to Buy Section of this Report

Market, By Treatment

• Surgery
• Radiation therapy
• Chemotherapy
• Targeted therapy
• Tumor treating field therapy
• Immunotherapy

Market, By Drug Class

• Temozolomide
• Bevacizumab
• Lomustine
• Carmustine wafers

Market, By Dosage Form

• Oral
• Parenteral

Market, By Gender

• Male
• Female

Market, By End-use

• Hospitals
• Cancer treatment centers
• Ambulatory surgical centers
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE
  • Rest of Middle East and Africa